Generation and Characterization of a Novel Recombinant Antibody Against LMP1-TES1 of Epstein-Barr Virus Isolated by Phage Display

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2013 Apr 24

PMID 23609879

Citations 9

Authors

Dawei Zhang

Yuan Mao

Qing Cao

Lin Xiong

Juan Wen

Renjie Chen

Jin Zhu

Affiliations

Soon will be listed here.

Abstract

Latent Membrane Protein 1 (LMP1) is a primary target for controlling tumorigenesis in Epstein-Barr virus related malignancies; in this study, we aimed to develop a specific antibody against the TES1 domain of the oncogenic LMP1. We screened a full human naïve Fab phage library against TES1 peptide, which consisted of C terminal-activating regions proximal 44 amino acids. After three rounds of panning, enrichment and testing by phage ELISA and further analyzed by DNA sequencing, we selected a phage clone with the highest affinity to LMP1-TES1 and designated it as htesFab. The positive clone was expressed in Escherichia coli and the purified htesFab was characterized for its binding specificity and affinity to LMP1. ELISA, immunofluorescence and FACS analysis confirmed that htesFab could recognize LMP1 TES1 both in vitro and in LMP1 expressing HNE2-LMP1 cells. Furthermore, MTT assay showed that htesFab inhibited the proliferation of HNE2-LMP1 cells in a dose-dependent manner. In summary, this study reported the isolation and characterization of human Fab, which specifically targets the C terminal region/TES1 of LMP1, and has potential to be developed as novel tool for the diagnosis and therapy of Epstein-Barr virus related carcinoma.

Citing Articles

Antibody Phage Display Technology for Sensor-Based Virus Detection: Current Status and Future Prospects.

Guliy O, Evstigneeva S, Khanadeev V, Dykman L Biosensors (Basel). 2023; 13(6).

PMID: 37367005 PMC: 10296108. DOI: 10.3390/bios13060640.

Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Roth K, Wenzel E, Ruschig M, Steinke S, Langreder N, Heine P Front Cell Infect Microbiol. 2021; 11:697876.

PMID: 34307196 PMC: 8294040. DOI: 10.3389/fcimb.2021.697876.

The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Cheerathodi M, Meckes Jr D Future Virol. 2021; 13(12):863-887.

PMID: 34079586 PMC: 8168621. DOI: 10.2217/fvl-2018-0120.

A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.

Mao Y, Wang J, Zhang M, Fan W, Tang Q, Xiong S Oncotarget. 2016; 8(7):10954-10965.

PMID: 28009988 PMC: 5355237. DOI: 10.18632/oncotarget.14032.

Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.

Kuhn P, Fuhner V, Unkauf T, Moreira G, Frenzel A, Miethe S Proteomics Clin Appl. 2016; 10(9-10):922-948.

PMID: 27198131 PMC: 7168043. DOI: 10.1002/prca.201600002.

References

Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X . Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 2005; 31(1):41-54. DOI: 10.1385/mb:31:1:041. View

Piche A, Kasono K, Johanning F, Curiel T, Curiel D . Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther. 1999; 5(9):1171-9. DOI: 10.1038/sj.gt.3300706. View

Lin H, Mao Y, Zhang D, Li H, Qiu J, Zhu J . Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin. Anticancer Agents Med Chem. 2013; 13(8):1259-66. DOI: 10.2174/18715206113139990134. View

Tavladoraki P, Benvenuto E, Trinca S, De Martinis D, Cattaneo A, Galeffi P . Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature. 1993; 366(6454):469-72. DOI: 10.1038/366469a0. View

Li H, Chang Y . Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci. 2003; 10(5):490-504. DOI: 10.1007/BF02256110. View

Cheng H, Foong Y, Sam C, Prasad U, Dillner J . Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol. 1991; 29(10):2180-6. PMC: 270294. DOI: 10.1128/jcm.29.10.2180-2186.1991. View

Paramita D, Fachiroh J, Haryana S, Middeldorp J . Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. J Clin Virol. 2008; 42(4):343-52. DOI: 10.1016/j.jcv.2008.03.006. View

Moorthy R, Thorley-Lawson D . All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol. 1993; 67(3):1638-46. PMC: 237535. DOI: 10.1128/JVI.67.3.1638-1646.1993. View

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

10.

Eliopoulos A, Young L . LMP1 structure and signal transduction. Semin Cancer Biol. 2001; 11(6):435-44. DOI: 10.1006/scbi.2001.0410. View

11.

Sandberg M, Hammerschmidt W, Sugden B . Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol. 1997; 71(6):4649-56. PMC: 191686. DOI: 10.1128/JVI.71.6.4649-4656.1997. View

12.

Zhao Y, Wang Y, Zeng S, Hu X . LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J Clin Pathol. 2011; 65(1):41-5. DOI: 10.1136/jclinpath-2011-200198. View

13.

Rondon I, Marasco W . Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol. 1997; 51:257-83. DOI: 10.1146/annurev.micro.51.1.257. View

14.

Cattaneo A, Biocca S . The selection of intracellular antibodies. Trends Biotechnol. 1999; 17(3):115-21. DOI: 10.1016/s0167-7799(98)01268-2. View

15.

Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E . The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995; 80(3):389-99. DOI: 10.1016/0092-8674(95)90489-1. View

16.

Ai P, Wang T, Zhang H, Wang Y, Song C, Zhang L . Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol. 2012; 49(4):326-31. DOI: 10.1016/j.oraloncology.2012.10.001. View

17.

Tang J, Rohwader E, Chu I, Tsang R, Steinhagen K, Yeung A . Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol. 2007; 40(4):284-8. DOI: 10.1016/j.jcv.2007.09.006. View

18.

Devergne O, Cahir McFarland E, Mosialos G, Izumi K, Ware C, Kieff E . Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 1998; 72(10):7900-8. PMC: 110117. DOI: 10.1128/JVI.72.10.7900-7908.1998. View

19.

Cho W . Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer. 2007; 6:1. PMC: 1774581. DOI: 10.1186/1476-4598-6-1. View

20.

Hu L, Chen F, Zhen Q, Zhang Y, Luo Y, Zheng X . Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer. 1995; 31A(5):658-60. DOI: 10.1016/0959-8049(94)00468-k. View